Allarity Therapeutics: Phase 2 stenoparib shows median overall survival >25 months for platinum-resistant ovarian cancer

Allarity Therapeutics, Inc.

Median overall survival (mOS) now exceeds 25 months, not yet formally reached, in ongoing Phase 2 trial.
Two patients remain on therapy >24 months; one with BRCA wild-type shows benefit, typically precluded by PARP inhibitors.
Data presented at AACR 2025 Ovarian Cancer Conference; FDA draft guidance supports OS as endpoint for approval.
Stenoparib shows less myelotoxicity vs earlier PARP inhibitors, relevant after 2022 market withdrawal of some PARP inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.